How a cancer cell dies turns out to matter enormously — not just for clearing the tumor, but for whether the immune system mounts a lasting defense. This distinction is reshaping how oncologists think about combining chemotherapy, radiation, and immunotherapy, with real implications for treatment sequencing in clinical practice.
Immunogenic cell death (ICD) encompasses several distinct cell-death modalities — immunogenic apoptosis, pyroptosis, necroptosis, and hybrid programs like PANoptosis — each releasing a characteristic signature of danger-associated molecular patterns (DAMPs) and cytokines. These signals don't simply clear debris; they actively remodel the tumor microenvironment, recruiting and licensing specific immune cell subsets to sustain antitumor responses. A critical nuance emerging from recent work is timing: acute, transient ICD stimulates productive immune activation, whereas chronic or prolonged exposure to the same inflammatory signals paradoxically suppresses immunity and may even facilitate oncogenesis through sustained inflammatory remodeling.
This review lands at a pivotal moment in immuno-oncology. The field has long known that some chemotherapies — anthracyclines and oxaliplatin being classic examples — are more immunogenic than others, but the mechanistic granularity of why specific death programs produce qualitatively different immune outcomes is only now becoming tractable. The acute-versus-chronic dichotomy is particularly underappreciated clinically: it suggests that dosing schedules and treatment intervals for ICD-inducing agents may need optimization not just for tumor kill, but for immunological rhythm. For patients on checkpoint inhibitor combinations, this framing could inform why some regimens fail despite initial tumor cell killing. Limitations of this work are inherent to its review format — mechanistic claims derive from heterogeneous preclinical models, and translating ICD modality specificity into human trial design remains an open engineering challenge.